Select for export Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1016/j.biopsych.2014.04.010 PubMed 24882567 Copy citation Copy BibTeX Biological Psychiatry 2014-04-25 Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E Europe PMC Published psilocybin DepressionAnxietyBrain Imaging Clinical Trial More
Select for export A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.3109/00952990.2013.811513 PubMed 23968172 Copy citation Copy BibTeX The American Journal of Drug and Alcohol Abuse 2013-08-31 Burdick BV, Adinoff B. Europe PMC Published psilocybin AddictionMystical ExperienceClinical Trial Randomized Controlled Trial More
Select for export Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1093/cercor/bht178 PubMed 23861318 Copy citation Copy BibTeX Cerebral Cortex 2013-07-15 Bernasconi F, Schmidt A, Pokorny T, Kometer M, Seifritz E, Vollenweider FX. Europe PMC Published psilocybin Brain ImagingMechanism of ActionReceptor Pharmacology Observational Study More
Select for export Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1523/jneurosci.3007-12.2013 PubMed 23785166 Copy citation Copy BibTeX Journal of Neuroscience 2013-05-31 Kometer M, Schmidt A, Jäncke L, Vollenweider FX. Europe PMC Published psilocybin Receptor PharmacologyConsciousnessObservational Study Observational Study More
Select for export Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1503/jpn.120128 Copy citation Copy BibTeX Фундаментальные исследования (Fundamental Research) 2013-02-28 Young SN. Europe PMC Published psilocybin DepressionAnxietyMechanism of Action Clinical Trial More
Select for export Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1093/schbul/sbs117 PubMed 23044373 Copy citation Copy BibTeX Schizophrenia Bulletin 2012-10-07 Carhart-Harris RL, Leech R, Erritzoe D, Williams TM, Stone JM, Evans J Europe PMC Published psilocybin Brain ImagingDefault Mode NetworkAging Other More
Select for export The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1007/s00213-012-2811-0 PubMed 22836372 Copy citation Copy BibTeX Psychopharmacology 2012-07-26 Schmidt A, Kometer M, Bachmann R, Seifritz E, Vollenweider F. Europe PMC Published psilocybin Receptor PharmacologyEmotional Processing Other More
Select for export Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1016/j.biopsych.2012.04.005 PubMed 22578254 Copy citation Copy BibTeX Biological Psychiatry 2012-05-09 Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX. Europe PMC Published psilocybin DepressionMechanism of ActionReceptor Pharmacology Clinical Trial More
Select for export High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1007/s00213-012-2680-6 PubMed 22526529 Copy citation Copy BibTeX Unknown journal 2012-04-12 Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Griffiths RR. Europe PMC Published psilocybin AnxietyHeadache / MigraineSpirituality Observational Study More
Select for export Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1192/bjp.bp.111.103309 PubMed 22282432 Copy citation Copy BibTeX The British Journal of Psychiatry 2012-01-25 Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T Europe PMC Published psilocybin Brain ImagingAgingEmotional Processing Clinical Trial More
Select for export Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1073/pnas.1119598109 PubMed 22308440 Copy citation Copy BibTeX Proceedings of the National Academy of Sciences 2012-01-22 Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A Europe PMC Published psilocybin Brain ImagingConsciousnessAging Other More
Select for export Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1038/npp.2011.261 PubMed 22030715 Copy citation Copy BibTeX Unknown journal 2011-10-25 Schmidt A, Bachmann R, Kometer M, Csomor PA, Stephan KE, Seifritz E Europe PMC Published psilocybin Mechanism of ActionReceptor PharmacologyConsciousness Other More
Select for export Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1038/npp.2011.228 PubMed 21956447 Copy citation Copy BibTeX Neuropsychopharmacology 2011-09-27 Quednow BB, Kometer M, Geyer MA, Vollenweider FX. Europe PMC Published psilocybinpsilocin Receptor PharmacologyConsciousnessObservational Study Clinical Trial More
Select for export Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1007/s00213-011-2358-5 PubMed 21674151 Copy citation Copy BibTeX Psychopharmacology 2011-06-14 Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Europe PMC Published psilocybin AnxietySpiritualityMystical Experience Clinical Trial More
Select for export The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1016/j.biopsych.2010.10.002 PubMed 21126732 Copy citation Copy BibTeX Biological Psychiatry 2010-12-02 Kometer M, Cahn BR, Andel D, Carter OL, Vollenweider FX. Europe PMC Published psilocybin Receptor PharmacologyConsciousness Other More
Select for export Investigating the Mechanisms of Hallucinogen-Induced Visions Using 3,4-Methylenedioxyamphetamine (MDA): A Randomized Controlled Trial in Humans Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1371/journal.pone.0014074 PubMed 21152030 Copy citation Copy BibTeX PLoS ONE 2010-12-01 Matthew J. Baggott, Jennifer D. Siegrist, Gantt P. Galloway, Lynn C. Robertson, Jeremy Coyle, John Mendelson OpenAlex Published psilocybin PharmacologyMechanism of ActionReceptor Pharmacology Randomized Controlled Trial More
Select for export Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1177/0269881110382466 PubMed 20855349 Copy citation Copy BibTeX Journal of Psychopharmacology 2010-09-19 Studerus E, Kometer M, Hasler F, Vollenweider FX. Europe PMC Published psilocybin AnxietyObservational StudySafety Observational Study More
Select for export Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1001/archgenpsychiatry.2010.116 PubMed 20819978 Copy citation Copy BibTeX Archives of General Psychiatry 2010-09-05 Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL Europe PMC Published psilocybin DepressionAnxietyAging Other More
Select for export Determining the subjective effects of TFMPP in human males. Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1007/s00213-010-1911-y PubMed 20552171 Copy citation Copy BibTeX Unknown journal 2010-06-15 Jan RK, Lin JC, Lee H, Sheridan JL, Kydd RR, Kirk IJ Europe PMC Published psilocybin AnxietyAddictionReceptor Pharmacology Observational Study More
Select for export The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series Abstract available at the source but not redistributed here. Read at source. Details DOI 10.1177/0333102410363490 PubMed 20713566 Copy citation Copy BibTeX Cephalalgia 2010-03-25 Matthias Karst, John H. Halpern, Michael Bernateck, Torsten Passie OpenAlex Published psilocybin Chronic PainHeadache / MigraineMechanism of Action Clinical Trial More
